Real-world Study on Dapagliflozin Usage in Patients With Heart Failure (HF) in Germany (EvolutionHF-DE)
Early Treatment of Heart Failure: a Non-interventional Study Program of Patients With Heart Failure and Initiated on Dapagliflozin (EVOLUTION-HF DEallEF)
Sponsor: AstraZeneca
This observational or N/A phase trial investigates Cardiovascular Diseases and Heart Diseases and is currently ongoing. AstraZeneca leads this study, which shows 16 recorded versions since 2024 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
16 versions recorded-
Feb 2026 — Present [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Nov 2025 — Feb 2026 [monthly]
Recruiting
-
Oct 2025 — Nov 2025 [monthly]
Recruiting
-
Sep 2025 — Oct 2025 [monthly]
Recruiting
-
Aug 2025 — Sep 2025 [monthly]
Recruiting
▶ Show 11 earlier versions
-
May 2025 — Aug 2025 [monthly]
Recruiting
-
Mar 2025 — May 2025 [monthly]
Recruiting
-
Feb 2025 — Mar 2025 [monthly]
Recruiting
-
Jan 2025 — Feb 2025 [monthly]
Recruiting
-
Dec 2024 — Jan 2025 [monthly]
Recruiting
-
Oct 2024 — Dec 2024 [monthly]
Recruiting
-
Sep 2024 — Oct 2024 [monthly]
Recruiting
-
Aug 2024 — Sep 2024 [monthly]
Recruiting
-
Jul 2024 — Aug 2024 [monthly]
Recruiting
-
Jun 2024 — Jul 2024 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Apr 2024 — Jun 2024 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aachen, Germany , Alsfeld, Germany , Bamberg, Germany , Bechhofen, Germany , Bergisch Gladbach, Germany , Berlin, Germany , Brilon, Germany , Bruchsal, Germany , Chemnitz, Germany , Dinslaken, Germany and 33 more locations